News

Technology News

Biscayne Pharma Nets Venture Capital Debt

Friday, November 6, 2015 5:04:00 AM PDT | VentureDeal
   Miami, Florida  --  Biscayne Pharmaceuticals has received $609,000 in new venture capital debt funding, according to an SEC regulatory filing.

Biscayne is developing therapies based on growth hormone-releasing hormone analogs (GHRH).

Investors in the financing weren't disclosed, nor was how the company intends to use the funding proceeds.

Biscayne is still seeking $1.4 million in additional debt investment, according to the filing.

Sameul Reich is currently the Executive Chairman of the company, and was previously president and CEO.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1